Absci reports business updates and fourth quarter and full year 2024 financial and operating results

Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by ai platform at 2024 r&d day entered into collaboration with amd, including $20 million strategic investment in absci achieved 2024 outlook for drug creation partnerships through collaborations with owkin, twist bioscience, invetx, and memorial sloan kettering cancer center cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 vancouver, wash. and new york, march 18, 2025 (globe newswire) -- absci corporation (nasdaq: absi), a data-first generative ai drug creation company, today reported financial and operating results for the quarter and full year ended december 31, 2024.
ABSI Ratings Summary
ABSI Quant Ranking